Citations

Mayo Clinic

Showing 10 of 108599 citations.

A Man with Recurrent Ascites after Laparoscopic Cholecystectomy
Sepiashvili, Lusia, Dahl, Ashley R, Meeusen, Jeffrey W. , Loftus, Conor G., Donato, Leslie J.

Clinical Chemistry | June 28, 2017 | Volume: 63 | Issue: 7 | Pages: 1199-1202

10.1373/clinchem.2016.263756 | PMID 28659396 Get It

Rehabilitation for the Anterior Cruciate Ligament-deficient Knee
Chmielewski, Terese L. , Hurd, Wendy J.

Update on Anterior Cruciate Ligament Injuries | June 28, 2017 | Volume: No volume available | Issue: No issue available | Pages: 1-32

10.17832/isc.2009.19.1.4 Get It

Use of Electroconvulsive Therapy in Dementia-Related Agitation
Burton, M. Caroline , Koeller, Sandra L., Brekke, Frank M., Afonya, Adonye T., Sutor, Bruce, Lapid, Maria I.

The Journal of ECT | June 28, 2017 | Volume: 33 | Issue: 4 | Pages: 286-289

10.1097/yct.0000000000000432 | PMID 28658012 Get It

Objectives This naturalistic prospective observation study examines the efficacy of electroconvulsive therapy (ECT) in treating dementia-related agitation. Methods Patients with dementia-related agitation who received ECT were compared with patients with the same condition who did not receive ECT using Cohen-Mansfield Agitation Inventory (CMAI), Neuropsychiatric Inventory (NPI)—nursing home version, and Clinical Global Impression Scale (CGI). Outcomes were compared between ECT-treated and non–ECT-treated patients. Results A total of 9 patients were included in the study. Six received ECT, and 3 did not. Patients in the ECT and non–ECT-treated groups had comparable baseline scores (CMAI, P = 0.880; NPI, P = 0.814; and CGI, P = 0.445). The CMAI, NPI, and CGI scores were lower on final assessment in both groups with no statistically significant difference (CMAI, P = 0.771; NPI, P = 0.243; and CGI, P = 0.519). Conclusions Electroconvulsive therapy should be considered as a treatment option in the management of severe treatment refractory dementia-related agitation.
Oncogenic Ect2 signaling regulates rRNA synthesis in NSCLC
Justilien, Verline , Lewis, Kayla C., Murray, Nicole R., Fields, Alan P.

Small GTPases | June 28, 2017 | Volume: 10 | Issue: 5 | Pages: 388-394

10.1080/21541248.2017.1335274 | PMID 28657426 Get It

IL ‐33: biological properties, functions, and roles in airway disease
Kita, Hirohito , Drake, Li Yin, Kita, H , Drake, Li Y.

Immunological Reviews | June 28, 2017 | Volume: 278 | Issue: 1 | Pages: 173-184

10.1111/imr.12552 | PMID 28658560 Get It

Summary Interleukin ( IL )‐33 is a key cytokine involved in type 2 immunity and allergic airway diseases. Abundantly expressed in lung epithelial cells, IL ‐33 plays critical roles in both innate and adaptive immune responses in mucosal organs. In innate immunity, IL ‐33 and group 2 innate lymphoid cells ( ILC 2s) provide an essential axis for rapid immune responses and tissue homeostasis. In adaptive immunity, IL ‐33 interacts with dendritic cells, Th2 cells, follicular T cells, and regulatory T cells, where IL ‐33 influences the development of chronic airway inflammation and tissue remodeling. The clinical findings that both the IL ‐33 and ILC 2 levels are elevated in patients with allergic airway diseases suggest that IL ‐33 plays an important role in the pathogenesis of these diseases. IL ‐33 and ILC 2 may also serve as biomarkers for disease classification and to monitor the progression of diseases. In this article, we reviewed the current knowledge of the biology of IL ‐33 and discussed the roles of the IL ‐33 in regulating airway immune responses and allergic airway diseases.
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel
Gleeson, Ferga C. , Voss, Jesse S. , Kipp, Benjamin R. , Kerr, Sarah E. , Arnam, John S. Van , Mills, John R. , Marcou, Cherisse A. , Schneider, Amber, Tu, Zheng Jin, Henry, Michael , Levy, Michael J. , Van Arnam, John S, Schneider, Amber R, Henry, Michael R, Levy, Michael J.

Oncotarget | June 28, 2017 | Volume: 8 | Issue: 55 | Pages: 93464-93475

10.18632/oncotarget.18750 | PMID 29212165 Get It

Educational Technologies for Physician Continuous Professional Development: A National Survey
Cook, David A. , Blachman, Morris J., Price, David W. , Thomas, Barbara L. Baasch, Berger, Richard A. , Wittich, Christopher M. , West, Colin P.

Academic Medicine | June 28, 2017 | Volume: 93 | Issue: 1 | Pages: 104-112

10.1097/acm.0000000000001817 | PMID 28658022 Get It

Purpose To determine the past experiences with, current use of, and anticipated use of online learning and simulation-based education among practicing U.S. physicians, and how findings vary by age. Method The authors surveyed 4,648 randomly sampled board-certified U.S. physicians, September 2015 to April 2016, using Internet-based and paper questionnaires. Survey items (some optional) addressed past and current technology usage, perceived technology effectiveness, and anticipated future use of specific technology innovations. Results Of 988 respondents, 444 completed optional items. Of these, 429/442 (97.1%) had used online learning and 372/442 (84.2%) had used simulation-based education in the past five years. Desire for more online learning was modest (mean [standard deviation], 4.6 [1.5]; 1 = strongly disagree, 7 = strongly agree), as was desire for more simulation-based education (4.2 [1.7]). Both online learning and simulation-based education were perceived as effective (5.2 [1.4]; 5.0 [1.4]). Physicians believed they possess adequate skills for online learning (5.8 [1.2]) and that point-of-care learning is vital to effective patient care (5.3 [1.3]). Only 39.0% used objective performance data to guide their learning choices, although 64.6% agreed that such information would be useful. The highest-rated innovations included a central repository for listing educational opportunities and tracking continuing education credits, an app to award credit for answering patient-focused questions, 5-minute and 20-minute clinical updates, and an e-mailed “question of the week.” Responses to most survey items were similar across age groups. Conclusions Practicing physicians generally seem receptive and prepared to use a variety of educational technologies, regardless of age.
Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson’s Disease
Tafreshi, Ali , Beach, Thomas G. , Tashiro, Stephanie, Wang, Charles , Dashtipour, Khashayar , Adler, Charles H. , Chen, Xin , Serrano, Geidy E. , Tashiro, Stephanie

Brain Sciences | June 28, 2017 | Volume: 7 | Issue: 7 | Pages: 74

10.3390/brainsci7070074 | PMID 28653979 Get It

Objective: To determine and compare DNA methylation patterns between patients with Parkinson’s disease (PD) and age- and sex-similar matched non-PD controls. Background: Epigenetic regulation is one of the major mechanisms for an organism to respond to the environment through changes in gene expression and has been implicated in numerous disease processes. We would like to examine epigenetic modification patterns that may predispose or protect against PD. Methods: Frozen tissue samples of the human cerebral cortex from 12 PD patients and 12 subjects without PD pathology were obtained. Genome-wide DNA methylation profiling was performed using the Illumina HumanMethylation450 BeadChip array. Differential methylation was defined as a mean methylation level difference (delta β) of at least 0.20 (Δβ ≥ 0.20). Methylation regions with an absolute delta β value ≥ 0.20 were selected for further gene function studies. Results: We identified 2795 differentially methylated CpG sites in the frontal cortex of PD cases with a detection p-value of ≤ 0.01 and 328 differentially methylated CpG sites with a detection p-value of ≤ 0.001. A pattern of robust hypermethylation of synphilin-1, α-synuclein-interacting protein (SNCAIP) gene was found in the brain of PD cases (p = 4.93 × 10−7 and delta β = 0.60). Conclusion: Our findings support a link between SNCAIP methylation and PD risk. Hypomethylation of SNCAIP may function to protect against PD. The current results may suggest that the methylation status of SNCAIP could be useful as a marker in PD diagnosis and treatment and warrants further investigation.
Vibrio vulnificus tonsillitis after swimming in the Gulf of Mexico
Alsaad, Ali A. , Sotello, David , Kruse, Brian, Cowart, Jennifer B. , Kruse, Brian T, Sotello Aviles, David A

BMJ Case Reports | June 28, 2017 | Volume: 2017 | Issue: No issue available | Pages: bcr-2017-221161

10.1136/bcr-2017-221161 | PMID 28659373 Get It

Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma
Jacobson, Blake A., Sadiq, Ahad A., Tang, Shaogeng , Jay-Dixon, Joe, Patel, Manish R. , Drees, Jeremy, Sorenson, Brent S., Russell, Stephen J. , Kratzke, Robert A. , Russell, Stephen J

Oncotarget | June 27, 2017 | Volume: 8 | Issue: 38 | Pages: 63096-63109

10.18632/oncotarget.18656 | PMID 28968974 Get It